8-KRegulation FDOther EventsExhibits & Filings

MCKESSON CORP 8-K Report, Regulation FD Disclosure (Nov 3, 2010)

Filed November 3, 2010For Securities:MCK

Summary

McKesson Corporation (MCK) has filed an 8-K report on November 2, 2010, to announce a significant development: the execution of a merger agreement with US Oncology Holdings, Inc. This transaction, dated November 1, 2010, involves McKesson's wholly-owned subsidiary, Utah Acquisition Corporation, acquiring US Oncology. The company also held a conference call for investors and analysts on the same day to discuss this acquisition. The filing includes the press release announcing the merger agreement and the full text of the agreement itself. Investors should note that while the agreement details the terms and conditions of the merger, the representations and warranties within it are made between the parties and may not reflect definitive factual statements or be directly applicable to shareholders for assessing factual information. The primary focus of this report is the disclosure of this material event, signaling a strategic move by McKesson.

Key Highlights

  • 1McKesson Corporation (MCK) announced the execution of a Merger Agreement with US Oncology Holdings, Inc. on November 1, 2010.
  • 2The transaction involves McKesson's subsidiary, Utah Acquisition Corporation, acquiring US Oncology.
  • 3A joint press release detailing the merger was issued by McKesson and US Oncology.
  • 4McKesson hosted an investor and analyst conference call on November 1, 2010, to discuss the merger announcement.
  • 5The 8-K filing includes the Merger Agreement as an exhibit, providing full details of the terms and conditions.
  • 6The company emphasizes that representations and warranties in the Merger Agreement are for contractual allocation of risk and should not be relied upon as factual statements by stockholders.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly disclose McKesson Corporation's execution of a Merger Agreement to acquire US Oncology Holdings, Inc. It also provides access to related documents like the press release and the merger agreement itself.

McKesson Corporation is acquiring US Oncology Holdings, Inc. through its wholly-owned subsidiary, Utah Acquisition Corporation.

This 8-K filing primarily focuses on the announcement and the merger agreement itself. It does not contain detailed financial statements or the purchase price for the acquisition; those would typically be disclosed in subsequent filings or through other communications.

More information about the merger terms can be found in the exhibits attached to this 8-K filing, specifically Exhibit 99.2 (Press Release) and Exhibit 99.3 (Agreement and Plan of Merger).